Incyte's Zynyz secures approvals in anal cancer 4 years after FDA rejection
With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an initial snub from the agency.
With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an initial snub from the agency.
